Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,525 shares of the medical equipment provider’s stock after selling 2,052 shares during the period. Texas Permanent School Fund Corp’s holdings in Hologic were worth $3,783,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic in the fourth quarter valued at about $27,000. Massmutual Trust Co. FSB ADV lifted its position in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares during the period. Allworth Financial LP lifted its position in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the period. Mather Group LLC. acquired a new stake in Hologic in the first quarter valued at about $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its position in Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HOLX. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. increased their target price on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Evercore ISI dropped their target price on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a report on Tuesday, July 2nd. Stephens began coverage on shares of Hologic in a report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 target price for the company. Finally, Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and an average price target of $85.55.

Hologic Trading Up 1.6 %

Shares of HOLX opened at $77.69 on Friday. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45. The firm has a 50 day simple moving average of $74.02 and a 200-day simple moving average of $74.57. The stock has a market cap of $18.13 billion, a price-to-earnings ratio of 39.64, a price-to-earnings-growth ratio of 2.59 and a beta of 0.99. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the company earned $1.06 EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. Equities analysts forecast that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.